Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
This study has been terminated.
(Inability to recruit sufficient number of patients)
Information provided by:
First received: July 11, 2007
Last updated: July 23, 2009
Last verified: July 2009
The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate Alzheimer's disease.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Effect of EGb 761® on the Ratio of the Isoforms of the Protein Precursor of Beta Amyloid Platelets on Patients With Mild to Moderate Alzheimer's Disease. A Phase II, Randomised, Double-blind Trial, on Parallel Groups Versus Placebo.|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Ipsen:
Primary Outcome Measures:
- Effect of EGb 761® on the ratio of the isoform of the protein precursor of beta amyloid platelets.
Secondary Outcome Measures:
- Efficacy of EGb 761® on the cognitive functions and safety of EGb 761® at a dosage of 240 mg per day
|Study Start Date:||July 2005|
|Primary Completion Date:||April 2008 (Final data collection date for primary outcome measure)|
Contacts and Locations